Weekly Icodec versus Daily Glargine U100 in Type 2 Diabetes without Previous Insulin.

Julio RosenstockStephen C BainAmoolya GowdaEsteban JódarBo LiangIldiko LingvayTomoyuki NishidaRoberto TrevisanOfri Mosenzonnull null

Published in: The New England journal of medicine (2023)

Glycemic control was significantly better with once-weekly insulin icodec than with once-daily insulin glargine U100. (Funded by Novo Nordisk; ONWARDS 1 ClinicalTrials.gov number, NCT04460885.).

Keyphrases

glycemic control
type diabetes
blood glucose
weight loss
insulin resistance
physical activity
cardiovascular disease
skeletal muscle